Who is sponsoring NCT04077021?

NCT04077021 is sponsored by Calibr, a division of Scripps Research.

What condition does NCT04077021 study?

NCT04077021 studies Metastatic Castration-Resistant Prostate Adenocarcinoma.

What is the status of NCT04077021?

NCT04077021 is currently TERMINATED.

Last reviewed 2023-05-12 · How we verify

First-in-human Study of CCW702 in Patients With Metastatic Castration Resistant Prostate Cancer

NCT04077021 PHASE1 TERMINATED

CCW702 is an investigational immunotherapy for prostate cancer. This is a two-part, first-in-human study to assess the safety and tolerability of CCW702 administered subcutaneously to patients with metastatic, castration resistant prostate cancer. Part I is divided in to two subparts, in both subparts patients will receive ascending dosages of CCW702 with the goal to determine the maximum tolerated dose (MTD) of CCW702 and efficacious regimen. Part Ia will explore every other other day dosing (QOD); Part Ib will explore weekly dosing (Q7D). In part II of the study, patients will be given the recommended part/phase 2 dose (RP2D) Q7D. The study will also assess the pharmacokinetics and pharmacodynamics of CCW702.

Details

Lead sponsor	Calibr, a division of Scripps Research
Phase	PHASE1
Status	TERMINATED
Enrolment	22
Start date	Fri Jul 17 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Oct 21 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Metastatic Castration-Resistant Prostate Adenocarcinoma

Interventions

CCW702

Countries

United States